Building a Future without Blindness due to Retinopathy of Prematurity in India: Progress, Challenges, and the Way Forward
- PMID: 40705223
- DOI: 10.1007/s13312-025-00142-1
Building a Future without Blindness due to Retinopathy of Prematurity in India: Progress, Challenges, and the Way Forward
Abstract
Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness in India. We examined the progress, current status, and challenges related to ROP in India. Despite national guidelines and initiatives, the coverage of ROP screening remains highly variable across regions. Key challenges include lack of screening facilities, trained personnel, inadequate awareness, and delayed referrals. Successful strategies include capacity building, quality improvement approaches, and telescreening. We recommend policy actions, including mandatory ROP screening arrangements by neonatal care facilities, raising community awareness, and the inclusion of ROP indicators in health system monitoring. Leveraging digital technologies and focusing on primary prevention through improved quality of neonatal care are crucial. With sustained commitment and intersectoral collaboration, India can create a comprehensive model for neonatal eye care for low- and middle-income countries, preventing ROP-related visual impairment and ensuring the right to sight for all infants.
Keywords: Indirect ophthalmoscopy; Premature birth; Visual impairment; Wide-field digital retinal imaging.
© 2025. The Author(s), under exclusive licence to Indian Academy of Pediatrics.
Conflict of interest statement
Declarations. Conflict of interest: None.
Similar articles
-
Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants.Cochrane Database Syst Rev. 2018 Mar 2;3(3):CD011893. doi: 10.1002/14651858.CD011893.pub2. Cochrane Database Syst Rev. 2018. PMID: 29499081 Free PMC article.
-
Supplemental oxygen for the treatment of prethreshold retinopathy of prematurity.Cochrane Database Syst Rev. 2003;2003(2):CD003482. doi: 10.1002/14651858.CD003482. Cochrane Database Syst Rev. 2003. PMID: 12804470 Free PMC article.
-
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.Cochrane Database Syst Rev. 2018 Jan 8;1(1):CD009734. doi: 10.1002/14651858.CD009734.pub3. Cochrane Database Syst Rev. 2018. PMID: 29308602 Free PMC article.
-
Retinopathy of Prematurity.2025 Jun 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jun 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32965990 Free Books & Documents.
-
Validation of postnatal growth and retinopathy of prematurity (G-ROP) screening guidelines in a tertiary care hospital of Pakistan: A report from low-middle income country.PLoS One. 2024 May 9;19(5):e0302534. doi: 10.1371/journal.pone.0302534. eCollection 2024. PLoS One. 2024. Retraction in: PLoS One. 2025 Jun 30;20(6):e0327050. doi: 10.1371/journal.pone.0327050. PMID: 38722843 Free PMC article. Retracted.
References
-
- Kulkarni S, Gilbert C, Zuurmond M, Agashe S, Deshpande M. Blinding retinopathy of prematurity in western India: characteristics of children, reasons for late presentation and impact on families. Indian Pediatr. 2018;55:665–70. - PubMed
-
- Sivanandan S, Chandra P, Deorari AK, Agarwal R. Retinopathy of prematurity: AIIMS, New Delhi experience. Indian Pediatr. 2016;53(Suppl 2):S123–8. - PubMed